Skip to content
Screener

Erasca, Inc. ERAS Investing Cash Flow

Investing Cash Flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$1.61B-241%
Eli Lilly logo
Eli LillyLLY
-$15.4B-739%
Pfizer logo
PfizerPFE
$785M-76.0%
Amgen logo
AmgenAMGN
-$569M-46.3%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-$1.66B-4,939%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$9.64M-68.5%

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$6.34B+1,466%
Enterprise value$6.34B+1,533%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Debt / equity0.1×0.0×
Current ratio9.5×-2.8×

Where this comes from

Reported directly by Erasca, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Erasca, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216788
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Sales of marketable securities100,826
In-process research and development(150,000)
Purchases of property and equipment(36)(83)
Net cash (used in) provided by investing activities(243,830)34,265
Cash flows from financing activities:
Proceeds from issuance of common stock in underwritten offering258,750
Issuance costs associated with underwritten offering(16,044)
Proceeds from the exercise of stock options1,95833

Item 1. Financial Statements.

FAQ

What is Erasca, Inc.'s investing cash flow?
Erasca, Inc. (ERAS) reported investing cash flow of -$243.83M in Q1 2026.
How has Erasca, Inc.'s investing cash flow changed year-over-year?
Erasca, Inc.'s investing cash flow decreased by 811.6% year-over-year, from $34.27M to -$243.83M.
What is the long-term trend for Erasca, Inc.'s investing cash flow?
Over 3 years (2021 to 2025), Erasca, Inc.'s investing cash flow has grown at a 15.8% compound annual growth rate (CAGR), from -$64.59M to $100.43M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Erasca, Inc.'s investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude